Substances have good activity against Bacillus subtilis and Staphylococcus aureus. Activity against MRSA strains were in the low and sub-micromolar range. No anti-Gram-negative activity was observed.
EF-Tu was identified as target in pull-down experiments using biotinylated compound. Protein biosynthesis inhibition was detected in precursor incorporation experiments using unlabeled compound.
Protein biosynthesis inhibition was observed and EF-Tu identified as target protein. Protein biosynthesis is a clinically validated target. Comparative proteomics studies suggest that the mechanism of action is different from known EF-Tu inhibitors.
The technology is offered for licensing and further therapeutic development.
- Novel antibiotic class
- Activity against Gram-positive bacteria
- Inhibits translation – a validated target
In case of interest we are pleased to inform you about the patent Status.
Siegmund, D, et al. (2017) Benzannulated Re(I)-NHC complexes: synthesis, photophysical properties and antimicrobial activity. Dalton Trans. 46: 15269-79.